Combination Screening Background
NCATS’s matrix combination screening platform
can rapidly test the effect of different drug combinations on cellular,
molecular or biochemical processes that are relevant to a disease of interest, including COVID-19.
To better elucidate the dose-dependent activities in two-dimensional space, we have developed a state-of-the-art,
high-throughput drug combination screening system in 6x6 or 10x10 dose matrix format using a highly integrated robotics system
and custom data analysis software.